Nvision Biomedical Technologies
PrivateLast Round
Series B
May 13, 2026
Est. Valuation
$250M
Total Funding Raised
$55.25M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Nvision Biomedical Technologies operates in Healthcare & Life Sciences and is based in San Antonio, Texas. Its latest recorded funding round was a Series B round in May 2026.
Nvision Biomedical Technologies is a medical devices company that provides surgeons with implants paired with instrumentation and biologics to simplify and improve surgery procedures.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, 3D Printing, Advanced Materials
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nvision Biomedical Technologies Comparables
Compare Nvision Biomedical Technologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 4WEB Medical | 85% | |
| Zavation Medical Products | 82% | |
| Curiteva, Inc. | 78% |
For institutional investors. Book with your work email.
Nvision Biomedical Technologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 13, 2026 | ||||
| Debt | Apr 28, 2020 | ||||
| Seed | Sep 18, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nvision Biomedical Technologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Entrée Capital | Series B |
| Playground Global | Series B |
| European Investment Bank Group | Series B |
| CDP Venture Capital SGR | Series B |
| JPMorgan Chase & Co. | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 73% MoM, reaching 2.6K.
- May 13, 2026
$55M round led by Abbott Laboratories.
For institutional investors. Book with your work email.
Nvision Biomedical Technologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nvision Biomedical Technologies's valuation, stock price, and market status.
Is Nvision Biomedical Technologies a public or private company?
Nvision Biomedical Technologies is a private company.
What is the current stock price of Nvision Biomedical Technologies?
Nvision Biomedical Technologies is a private company, so its shares have no public market price. Caplight tracks Nvision Biomedical Technologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nvision Biomedical Technologies worth (valuation)?
Nvision Biomedical Technologies's valuation is estimated at $250.0M based on funding round data.
Can I buy Nvision Biomedical Technologies stock?
Nvision Biomedical Technologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nvision Biomedical Technologies's last funding round?
Nvision Biomedical Technologies's most recent funding round was Series B on May 13, 2026.
Who are the main investors in Nvision Biomedical Technologies?
Key investors in Nvision Biomedical Technologies include Entrée Capital, Playground Global, European Investment Bank Group, CDP Venture Capital SGR, JPMorgan Chase & Co..
Will Nvision Biomedical Technologies IPO soon?
No public IPO plans have been announced for Nvision Biomedical Technologies.
How can I track Nvision Biomedical Technologies secondary market activity?
Caplight tracks bids, offers, and trades in Nvision Biomedical Technologies's shares on secondary markets.